Skip to main content
. 2011 May 20;34(6):1369–1371. doi: 10.2337/dc10-2412

Table 1.

ROR of bladder cancer for antidiabetic drugs

Active substance Cases* All ADR ROR 95% CI P†
Pioglitazone 31 37,841 4.30 2.82–6.52 <0.001
Insulin 29 124,873 1.01 0.06–1.55 0.961
Metformin 25 138,900 0.73 0.46–1.15 0.158
Glimepiride 13 35,388 1.66 0.89–3.01 0.080
Exenatide 8 100,946 0.30 0.14–0.64 0.001
Gliclazide 6 7,560 3.56 1.42–8.39 0.001
Glipizide 5 34,816 0.61 0.22–1.54 0.272
Sitagliptin 4 11,638 1.51 0.48–4.22 0.416
Acarbose 4 3,479 5.12 1.61–14.33 <0.001
Rosiglitazone 4 44,006 0.38 0.12–1.05 0.045
Glibenclamide 3 38,214 0.33 0.08–1.06 0.043
Nateglinide 2 4,994 1.75 N.A. N.A.
Repaglinide 2 6,060 1.44 N.A. N.A.
Phenformin 1 65 68.30 N.A. N.A.
Voglibose 1 2,938 1.48 N.A. N.A.
Other antidiabetic drugs 0 7,367 N.A. N.A. N.A.
Total 138 599,085

ADR, adverse drug reaction; N.A., not available.

*Cases of bladder cancer.

†Mantel-Haenszel corrected.